Background: Despite being a high burden disorder, the pathogenesis of severe refractory asthma (SRA) is poorly understood. There are some evidences for the involvement of members of the signal transducer and activator of transcription (STAT) family, including STAT3 and STAT5a. Our study aimed to evaluate the gene expression of STAT3 and STAT5a in asthma and SRA to establish if there is an association.
INTRODUCTION
Chronic asthma is a non-communicable inflammatory airway disorder in which patients present with recurring bouts of breathlessness and wheezing. Although the exact pathogenesis of asthma is not fully understood, numerous causative environmental and/or triggering agents have been described. These include allergens, tobacco smoke, chemical irritants, and microorganisms. These factors interact with an individual's genetic and epigenetic background, leading to the development of asthma or the triggering of attacks (1) .
Asthma is suspected to cause approximately 250,000 premature deaths annually and the World Health Organization (WHO) estimates that more than 300 million individuals are affected worldwide. This number is predicted to increase to 400 million by 2025. Due to the fact that asthma is a major cause of disability, poor quality of life, increased health resource utilization, and is a public health concern, it is essential to fully understand the genetic basis of the disease (2, 3) . There is some evidence supporting the involvement STAT3 and STAT5 in the development of asthma (18, 19) .
STAT3 has been demonstrated to be involved in airway inflammation, allergy, and asthma through several proposed mechanisms. These include the Th2/Th17 immune responses and epidermal growth factor receptor (EGFR) signaling (20) (21) (22) . Furthermore, it has been proposed that STAT3 is a potential target for asthma and SRA therapeutics (23) . However, there are also several studies that discount a role for STAT3 in asthma (24, 25) . This suggests that STAT5 may be involved in asthma through mast cell pathogenesis (8, 26) and there have been several studies supporting such a link (27) (28) (29) (30) (31) . The association between asthma and the STAT5b isoform has been the most well studied relationship to date but a potential role for the STAT5a isoform is unclear (14) . A previous study by Tsitsiou et al. that evaluated gene expression in patients with severe asthma reported that STAT3 and STAT5b expression levels were 1.59 and 1.62 times higher, respectively in these patients (3). Our study, therefore, aimed to investigate STAT3 and STAT5 gene expression in asthma and SRA. Table 2 summarizes the demographics of the participants. The mean age was significantly different between healthy individuals and both asthma groups, mainly due to the voluntary nature of the study.
MATERIALS AND METHODS

Our study was a joint investigation by the
RESULTS
Participant Characteristics
Additionally, 90% of the controls were male, while 61%
were male for the mild asthma group and 64% for the SRA group. Patient body mass indices (BMIs) were used as a general gauge of the nutritional condition and physical health of participants. This was found to be approximately 26.40 across the three studied groups (P-value = 0.99).
Finally, the ethnicities of participants were found to be similar in each of the three groups (60% Fars, 8% Turks, 12% Lores, and 20% Kurds).
Comparison of Transcript Abundance
Student's t-tests comparing the qRT-PCR data revealed that the transcript expressions of STAT3 and STAT5A were not significantly different between genders (Tables 3 and   4 ). STAT3 and STAT5a transcript expressions also did not correlate with age of all participants (r=0.42, P-value=0. 35 for STAT3 and r=0.31, P-value=0.67 for STAT5a).
Furthermore the gene expression (mean ΔCts) of STAT3
and STAT5A were compared by ANOVA statistical tests between cases and control groups. showed the expression ratios of asthma and SRA groups against the control group are 1.096 and 1.013 respectively, when the control adjusted to 1 (Figure 1 ). These findings show the level of STAT3 gene expression in asthma group is followed by SRA and control groups.
When examining STAT5a transcript levels, we found a significant difference between the disease groups (P-value=0.03) ( Table 4) . A Tukey's post hoc test suggested that the only significant difference was between healthy and SRA groups (P-value=0.04). The P-value for a putative difference between the mild asthma versus SRA groups, and the asthma versus healthy groups, were 0.83 and 0.15, respectively. Fold change analysis (2 -ΔΔCt ) revealed the highest STAT5a transcript levels were in healthy controls, followed by the mild asthma and then SRA groups (the control group was set to 1.0) (Figure 2 ). 
DISCUSSION
Considering all participants, the STAT3 and STAT5a gene expressions were not associated with age and significantly different in both sexes. Thus, significant differences of age and gender between the study groups are not confounding factors. Also, similarity in BMI and ethnicity of the groups shows that participants' physical conditions and genetic backgrounds do not affect the results.
As the steroid regimens and pulmonary function tests of all participants were variable, there was possibility that these factors interfere with our results. To reduce these effects, we applied certain standards restrictedly to prevent bias. For example, the cases were selected if they had diagnostic criteria of GINA (for asthma) and IMI (for SRA) for more than 2 years and had no experience of exacerbation in the 6 months prior to sampling.
Furthermore, they were controlled by inhaled corticosteroids which have least systemic effects (34).
STAT3
As previously mentioned, the role of STAT3 in the pathogenesis of asthma and SRA is somewhat controversial. Our study revealed that STAT3 gene expression was not significantly different between the three groups of healthy controls, asthma and severe asthma. This finding is compatible with some reports. For example, Chiba et al. found that STAT3 had no notable role in the pathogenesis of bronchial allergic asthma (24, 25) .
Furthermore, the polymorphic relation of asthma and STAT3 has been denied previously (35) and intracellular flow cytometry of CD4(+)CD161(+) T cells found no differences in phosphorylated STAT3 levels between patients with asthma and controls (36) . On the other hand, many studies signify the STAT3 role in pathogenesis of asthma and SRA (18) (19) (20) (21) (22) (23) . It is also believed that airway remodeling may be influenced by STAT3 (37) (38) (39) (40) .
Based on our results and previous studies, we hypothesize that, STAT3 may have some role in the metabolic pathways of asthma, however, it does not seem to be directly involved in the pathogenesis of asthma and SRA. Meanwhile, the controversies in studies may be due to different methods used in each study, the individual role of the three STAT3 isoforms, an inadequate sample size, or even unknown confounding factors.
STAT5a
In contrast to STAT3, we found a significant difference in the transcript levels of STAT5a between the study groups. The STAT5a expression in healthy controls was nearly twice of patients with asthma. 
CONCLUSION
In conclusion, we found no evidence to support the suggestion that STAT3 is involved in asthma and SRA.
Further investigation may provide more information to elucidate its role in respiratory inflammation disorders.
Meanwhile, down regulation of STAT5a in asthma, and especially SRA, is a notable finding which worth to be considered more in future studies. Using transcriptomic and proteomic methods with higher sample size, the expression study of STAT5a, STAT5b and total STAT5 may provide considerable results on their roles in asthma pathogenesis.
